1.Yang SC, Hsueh PR, Lai HC, Teng LJ, Huang LM, Chen JM, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003; 47:1958-1962.
2.Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31:1209-1215.
3.Woods GL, Bergmann JS, Witebsky FG, Fahle GA, Boulet B, Plaunt M, et al. Multisite reproducibility of E-test for susceptibility testing of Mycobacterium abscessus, M. chelonae, and M. fortuitum. J Clin Microbiol 2000; 38:656-661.
4.Kim H, Kim SH, Shim TS, Kim MN, Bai GH, Park YG, et al. PCR restriction fragment length polymorphism analysis (PRA)-algorithm targeting 644 bp Heat Shock Protein 65 (hsp65) gene for differentiation of Mycobacterium spp. J Microbiol Methods 2005; 62:199-209.
5.Martin-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004; 8:1186-1193.
6.Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. ATS mycobacterial diseases subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:365-416.
7.Brown-Elliott BA, Wallace RJJ. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15:716-746.
8.Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. US Department of Health and Human Services publication (CDC).no. 86-8230. Centers for Disease Control, Atlanta, Ga. US: Public Health Service publication; 1995.
9.Shojaei H, Magee JG, Freeman R, Yates M, Horadagoda NU, Goodfellow M. Mycobacterium elephantis sp. nov, a rapidly growing non-chromogenic Mycobacterium isolated from an elephant. Int J Syst Evol Microbiol 2000; 5:1817-1820.
10.Khan IU, Yadav JS. Development of a single-tube, cell lysis-based, genus-specific PCR method for rapid identification of mycobacteria: optimization of cell lysis, PCR primers and conditions, and restriction pattern analysis. J Clin Microbiol 2004; 42:453-457.
11.Sahm DF, Washington II JA. Antibacterial susceptibility tests: dilution methods. In: Balows A. editor. Manual of Clinical Microbiology. 5thed. Washington, DC: American Society for Microbiology; 1991.p.1105-1116.
12.NCCLS. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes. Approved standard M24-A, Vol. 23. NCCLS, Villanova, Pa. 2003.
13.American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-S25.
14.Lee SM, Kim JM, Jeong J, Park YK, Bai GH, Lee EY, et al. Evaluation of the broth microdilution method using 2,3-Diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing. J Korean Med Sci 2007; 22:784-790.
15.Foo H, Hal S van, Jelfs P, Gilbert GL. Antimicrobial resistance in non-tuberculous mycobacteria in New South Wales, 2002-2008. Int J Antimicrob Agents 2009; 34:182-184.
16.Wallace RJ, Dalovisio JR, Pankey GA. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents. Antimicrob Agents Chemother 1979; 16:611-614.